Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Who May Qualify: - Patients must be ≥ 18 years of age - diagnosed by tissue sample (biopsy-confirmed) diagnosis of metastatic solid tumors - Eastern Cooperative Oncology Group (ECOG) performance status 0-1 - All patients should have at least 1 tumors that can be measured on scans v1.1. An irradiated lesion can be considered measurable only if progression has been demonstrated on the irradiated lesion. - All contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. - Adequate hematologic, hepatic and renal function - Capable of giving signed willing to sign a consent form Who Should NOT Join This Trial: - Any clinically significant cardiac disease - Unresolved toxicities from previous anticancer therapy - Prior solid organ or hematologic transplant - Known untreated, active, or uncontrolled brain metastases - Known positivity with human weakened immune system virus (HIV), known active hepatitis B or C, or uncontrolled chronic or ongoing infectious requiring intravenous treatment. - Receipt of a live-virus vaccination within 28 days of planned treatment start - Patient not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions. - Participation in a concurrent clinical study in the treatment period. - Known hypersensitivity to MDX2001 or any of its ingredients The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial. Always talk to your doctor about whether this trial is right for you.